cas 1778-09-2|| where to buy 1-(4-(Methylthio)phenyl)ethanone

Nombre del producto:1-(4-(Methylthio)phenyl)ethanone

IUPAC Name:1-[4-(methylsulfanyl)phenyl]ethan-1-one

Unidad de embalaje	Stock disponible	Precio($)
CM250395-50g	in stock	Ǚƴ
CM250395-100g	in stock	ħŮƴ
CM250395-500g	in stock	ƈħǙ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1778-09-2 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1778-09-2; Fórmula molecular:C9H10OS; Punto de fusión:-; Código de sonrisas:CC(C1=CC=C(SC)C=C1)=O; Densidad:

: Número de catálogo:CM250395; Peso molecular:166.24; Punto de ebullición:135°C at 1 mmHg; Nº Mdl:MFCD00039835; Almacenamiento:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Elafibranor; Nov 13, 2023, ELATIVE® Phase III trial confirms potential for investigational elafibranor as a first-in-class, dual PPAR α,δ agonist for patients with Primary Biliary Cholangitis.
Elafibranor is a novel, oral, once-daily, dual peroxisome activated receptor (PPAR) alpha/delta (α,δ) agonist, currently under investigation as a treatment for patients with PBC, a rare liver disease. Concurrent α,δ activation targets inflammation, cholestasis and fibrosis in PBC.